Takeda (TAK) Q1 2026 earnings review
FX Masks Underlying Contraction as Takeda Navigates its 'Investment Year'
Takeda reported a 10.2% YoY revenue increase to JPY 1,219.9B, but this was entirely a mirage created by the weak Japanese yen. On a Constant Exchange Rate (CER) basis, revenue actually contracted by 0.5%. While the VYVANSE generic erosion is tapering, new cracks appeared: the previously touted Plasma-Derived Therapies (PDT) segment and TAKHZYRO both reversed into negative CER growth. Core Operating Profit was stable on a CER basis (-0.5%), but bottom-line Core EPS dropped 11.8% at CER, crushed by a massive 35.5% CER spike in tax expenses. Management maintained its full-year guidance, reaffirming FY26 as an earnings trough (Core OP guided down 5-8% CER) as they heavily fund R&D for their upcoming 'Big Three' pipeline launches.
🐂 Bull Case
Driven by FRUZAQLA (+26.8% CER) and ADCETRIS (+14.4% CER), the Oncology segment grew a robust 8.2% at CER, proving Takeda can successfully commercialize its newer targeted therapies.
The massive Neuroscience revenue drops seen in FY25 are normalizing. The segment declined only 4.8% CER in Q1, suggesting the worst of the patent cliff base-effects are in the rearview mirror.
🐻 Bear Case
Management previously claimed plasma headwinds were 'temporary'. However, Q1 PDT revenue reversed to a 2.1% CER decline, with both Immunoglobulin (-0.6%) and Albumin (-5.0%) shrinking amid fierce global pricing pressure.
Core Income Tax Expenses spiked 35.5% CER due to Deferred Tax Asset reassessments and US international tax provisions, driving Core Net Profit down 10.9% CER despite flat operating margins.
⚖️ Verdict: ⚪
Neutral to Bearish. While the pipeline promises long-term salvation, the near-term operational reality is weak. Ex-FX, the company is shrinking, key growth pillars (PDT, TAKHZYRO) are deteriorating, and tax burdens are worsening the 'investment year' earnings trough.
Key Themes
Plasma-Derived Therapies Reversing to Contraction
A specific data point contradicts management's positive Q4 narrative: the PDT segment fell 2.1% CER in Q1. During the FY25Q4 call, management brushed off plasma weakness as 'temporary' and 'returning to a more normalized state'. Yet, Immunoglobulin revenue fell 0.6% CER and Albumin dropped 5.0% CER in Q1. Increased global supply is driving severe price competition, structurally challenging the mid-single-digit long-term growth thesis for this JPY 1+ trillion segment.
TAKHZYRO Market Share Erosion
The Rare Diseases segment decelerated to a 5.8% CER decline, heavily weighed down by TAKHZYRO, which dropped 2.2% CER to JPY 59.9B. The company explicitly cited 'increased competition in the U.S.' This validates long-standing analyst concerns regarding new competitive entrants (like Ionis' donidalorsen) eroding Takeda's stronghold in hereditary angioedema.
FRUZAQLA and ADCETRIS Driving Oncology
Oncology was a standout driver, accelerating to 8.2% CER growth (JPY 165.6B). FRUZAQLA surged 26.8% CER due to strong uptake in European metastatic colorectal cancer markets. ADCETRIS also grew 14.4% CER, driven by Latin American demand. This segment is effectively buffering the losses in Neuroscience and Rare Diseases.
Pipeline 'Big Three' R&D Investment
Core R&D expenses increased 6.8% CER to JPY 167.4B. Takeda is actively executing its 'investment year' strategy, funneling capital into late-stage trials for elritercept, TAK-928, and TAK-921, while preparing for the critical H2 2026 launches of oveporexton (narcolepsy) and rusfertide (polycythemia vera). The Horizon 2 growth thesis relies entirely on these specific assets.
Severe Tax Headwinds
Core Income Tax Expenses skyrocketed 48.6% AER (35.5% CER) to JPY 79.3B. Management attributed this to a reassessment of Deferred Tax Asset recoverability, lower tax credits, and higher US international tax provisions. This dramatically widened the gap between operating performance (-0.5% Core OP at CER) and bottom-line returns (-10.9% Core Net Profit at CER).
Macro: Favorable FX Distorting Operational Reality
The extreme depreciation of the Japanese Yen is inflating reported metrics. Geographically, US revenue grew 4.1% AER but fell 5.2% CER. Europe grew 19.1% AER but only 4.9% CER. Investors must strip out the JPY 113.2B total revenue FX tailwind to see the underlying volumetric stagnation.
Other KPIs
Decelerating sharply, down 63.9% YoY from JPY 190.1B in 25Q1. Operating cash flow fell by JPY 87.8B primarily due to a JPY 134.5B negative swing in trade working capital (higher receivables from sales timing and higher PDT/ENTYVIO inventory build). Concurrently, capital expenditures and intangible asset acquisitions increased to support the pipeline.
Stable on a CER basis (+1.6% CER). Despite a 11.9% increase on an actual basis due to FX, the underlying cost control demonstrates that the transformation program and restructuring efforts are effectively offsetting the inflationary pressures of launching new products.
Leverage increased slightly from 2.6x at the end of FY25. With Adjusted Free Cash Flow currently compressed, rapid deleveraging toward the company's 2.0x target appears stalled in the near term.
Guidance
Stable compared to Q1's actual run rate of -0.5% CER. Indicates management does not expect a sudden acceleration in the back half of the year, acknowledging that new product volume will not yet offset mature brand erosion.
Decelerating. With Q1 Core OP essentially flat (-0.5% CER), the guidance implies significant margin compression in the remaining quarters of FY26. This aligns with planned increases in restructuring charges (JPY 170B total for FY26) and launch preparation costs.
Decelerating (-8.7% AER decline vs FY25's JPY 517). Management reiterated the 'Mid-teens % decline' at CER. This highlights that the Q1 tax spike is part of a structural full-year headwind, driven by a higher projected cash tax rate (Low 10s%) compared to FY25.
Key Questions
PDT structural vs temporary headwinds
Last quarter, plasma market oversupply and pricing pressures were dismissed as temporary. With Immunoglobulin and Albumin both shrinking at CER in Q1, at what point does management revise its long-term mid-single-digit growth target for PDT?
TAKHZYRO Defense Strategy
TAKHZYRO contracted 2.2% at CER in Q1. How exactly is Takeda adapting its commercial strategy in the US to defend against donidalorsen and other new market entrants?
Tax Rate Normalization
Core Income Tax Expenses surged over 35% at CER. Are the Deferred Tax Asset reassessments a one-time Q1 hit, or will this elevated tax burden persist throughout the entirety of the Horizon 1 investment period?